不同时间采用丙种球蛋白治疗川崎病的疗效比较
|
摘要
目的比较不同时间采用丙种球蛋白治疗川崎病的临床疗效。方法选取2015年5月至2018年10月患有川崎病患者123例,随机平均分为观察组和对照1组,对照2组各41例,观察组患者使用丙种蛋白治疗(1-5)d,对照1组治疗(5-10)d,对照2组患者治疗(>10)d。对比三组患者发生冠状动脉并发症以及冠状动脉瘤的发生率,丙种球蛋白无反应性发生的情况。结果观察组患者丙种球蛋白无反应性发生率(39.02%)显著高于对照1组(14.63%)、对照2组(7.32%),具有差异统计学意义(P<0.05)。对照2组患者冠状动脉并发症的发生率(29.27%)高于观察组(19.51%)和对照1组(17.07%),冠状动脉瘤的发生率(14.63%)也高于观察组(4.88%)和对照1组(2.44%),具有差异统计学意义(P<0.05)。结论使用丙种球蛋白治疗川崎病,在发病5-9d内无反应性情况、冠状动脉发病率以及冠状动脉瘤的发生率最低。可在临床治疗中进行使用和推广。
Objective To compare the clinical efficacy of gamma globulin in the treatment of Kawasaki disease at different times.Methods 123 patients with Kawasaki disease from May 2015 to October 2018 were randomly divided into two groups: observation group and control group, 41 cases in each group. Patients in observation group were treated with C protein(1-5) days, patients in control group 1(5-10) days, and patients in control group 2(more than 10) days. The incidence of coronary artery complications and coronary artery aneurysms and the occurrence of gamma globulin non-responsiveness were compared among the three groups. Results The incidence of immunoglobulin non-responsiveness in the observation group(39.02%) was significantly higher than that in the control group 1(14.63%) and the control group 2(7.32%) with statistical significance(P<0.05). The incidence of coronary artery complications in control group 2(29.27%) was higher than that in observation group(19.51%) and control group 1(17.07%). The incidence of coronary artery aneurysms(14.63%) was also higher than that in observation group(4.88%) and control group 1(2.44%) with statistical significance(P<0.05). Conclusion In the treatment of Kawasaki disease with gamma globulin, the incidence of non-responsiveness,coronary artery disease and coronary artery aneurysm is the lowest within 5-9 days of onset. It can be used and promoted in clinical treatment.
Objective To compare the clinical efficacy of gamma globulin in the treatment of Kawasaki disease at different times.Methods 123 patients with Kawasaki disease from May 2015 to October 2018 were randomly divided into two groups: observation group and control group, 41 cases in each group. Patients in observation group were treated with C protein(1-5) days, patients in control group 1(5-10) days, and patients in control group 2(more than 10) days. The incidence of coronary artery complications and coronary artery aneurysms and the occurrence of gamma globulin non-responsiveness were compared among the three groups. Results The incidence of immunoglobulin non-responsiveness in the observation group(39.02%) was significantly higher than that in the control group 1(14.63%) and the control group 2(7.32%) with statistical significance(P<0.05). The incidence of coronary artery complications in control group 2(29.27%) was higher than that in observation group(19.51%) and control group 1(17.07%). The incidence of coronary artery aneurysms(14.63%) was also higher than that in observation group(4.88%) and control group 1(2.44%) with statistical significance(P<0.05). Conclusion In the treatment of Kawasaki disease with gamma globulin, the incidence of non-responsiveness,coronary artery disease and coronary artery aneurysm is the lowest within 5-9 days of onset. It can be used and promoted in clinical treatment.
引文
[1]张根,李新萍,常丽.不同剂量丙种球蛋白联合阿司匹林治疗小儿川崎病的疗效分析[J].临床荟萃,2015(5):572-574.
[2]杨丽丽.大剂量丙种球蛋白联合阿司匹林治疗小儿川崎病的效果分析[J].临床医药文献电子杂志,2017(49):168+170.
[3]赵有丽,刘彩霞.阿司匹林联合大剂量丙种球蛋白治疗小儿川崎病的疗效及对血清脑利钠肽指标的影响[J].川北医学院学报,2018,161(02):28-30.
[4]郑丽萍.不同剂量丙种球蛋白治疗小儿川崎病的效果观察[J].齐齐哈尔医学院学报,2016(31):46-47.
[5]丁丹.不同剂量丙种球蛋白治疗小儿川崎病的临床疗效研究[J].临床医药文献电子杂志,2016,3(22):4378-4378.
[2]杨丽丽.大剂量丙种球蛋白联合阿司匹林治疗小儿川崎病的效果分析[J].临床医药文献电子杂志,2017(49):168+170.
[3]赵有丽,刘彩霞.阿司匹林联合大剂量丙种球蛋白治疗小儿川崎病的疗效及对血清脑利钠肽指标的影响[J].川北医学院学报,2018,161(02):28-30.
[4]郑丽萍.不同剂量丙种球蛋白治疗小儿川崎病的效果观察[J].齐齐哈尔医学院学报,2016(31):46-47.
[5]丁丹.不同剂量丙种球蛋白治疗小儿川崎病的临床疗效研究[J].临床医药文献电子杂志,2016,3(22):4378-4378.